Litcius/Paper detail

1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2

Catherine A. Shu, Keiko Goto, Yuichiro Ohe, Benjamin Besse, K. Park, Y. Wang, Frank Griesinger, James Chih‐Hsin Yang, Enriqueta Felip, Rachel E. Sanborn, R. Bernabe Caro, Joshua Bauml, J. Chen, E. Fennema, James Mahoney, Leonardo Trani, Roland E. Knoblauch, Meena Thayu, Byoung Chul Cho

2021Annals of Oncology20 citationsDOI

Topics & Concepts

OsimertinibMedicineLung cancerOncologyChemotherapynon-small cell lung cancer (NSCLC)Internal medicinePlatinumMutantCancerEpidermal growth factor receptorErlotinibGeneA549 cellBiologyBiochemistryCatalysisLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesGastric Cancer Management and Outcomes
1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 | Litcius